Mesoblast Limited (NASDAQ:MESO) Given Consensus Recommendation of “Buy” by Analysts

Shares of Mesoblast Limited (NASDAQ:MESO) have received a consensus rating of “Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $18.00.

A number of equities analysts have weighed in on MESO shares. Canaccord Genuity Group raised shares of Mesoblast to a “strong-buy” rating in a research note on Tuesday, August 5th. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Friday, July 18th.

Institutional Investors Weigh In On Mesoblast

Large investors have recently made changes to their positions in the business. Barclays PLC acquired a new stake in shares of Mesoblast in the fourth quarter worth $38,000. JPMorgan Chase & Co. acquired a new stake in shares of Mesoblast in the fourth quarter worth $50,000. BNP Paribas Financial Markets increased its position in shares of Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company’s stock worth $51,000 after acquiring an additional 2,597 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Mesoblast in the fourth quarter worth $88,000. Finally, Advisors Preferred LLC increased its position in shares of Mesoblast by 224.9% in the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company’s stock worth $54,000 after acquiring an additional 3,169 shares in the last quarter. Institutional investors and hedge funds own 1.43% of the company’s stock.

Mesoblast Trading Up 1.0%

NASDAQ:MESO opened at $14.85 on Friday. The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. Mesoblast has a fifty-two week low of $6.00 and a fifty-two week high of $22.00. The firm’s 50 day moving average is $12.80 and its two-hundred day moving average is $13.27.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.